StudyManager Evolve Gaining Momentum in Chinese Market
StudyManager announced that GCP ClinPlus Ltd and Chongqing Jiachen Biotechnology have deployed StudyManager’s Evolve software to manage their latest clinical studies.
Both deployments represent significant milestones for StudyManager, which began its expansion into China in early 2009. Demand for StudyManager Evolve, the company’s sponsor/CRO-focused product, has gained traction internationally following the success of numerous clinical trials and increased market share in the United States.
“We spent more than a year evaluating EDC systems that include both US. and Chinese vendors’ products,” said Dr. Ivan Zhai, CEO of GCP ClinPlus Ltd. “We selected Evolve as our EDC system because it is a simple, easy-to-use system that our sites are excited to use, with minimal user training. This should improve data entry compliance and data quality right from the start, while maintaining happy site users.”
Chongqing Jiachen Biotechnology Ltd. found Evolve to be flexible and easy to use—an ideal solution for managing data on behalf of the small- to mid-size biotechnology and pharmaceutical companies for which Chongqing Jiachen manages clinical trials.
Evolve's web-based interface integrates clinical trial management and electronic data capture tools. These features are highly scalable, and can be used together seamlessly or independently. Evolve enables users to create a single, centralized and secure location for key study information, simplifying study operations and enhancing team efficiency.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
